Prometheus Biosciences, Inc. RXDX
Set alert
199.92 0.00 0.00%
At close · Jun 15
199.92 Day range 199.96
52-week range unavailable
- Open
- 199.68
- Prev close
- 199.92
- Mkt cap
- 9.56B
- Vol
- 1.79M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 199.92
- High
- 199.96
- Forward P/E
- -44.33
- Beta
- -0.49
- Short ratio
- 3.97
- Inst. own
- 81.01%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 10, 2023
- 50-d avg
- 189.46
- 200-d avg
- 112.93
- 1y target
- 190.00
2Y chart
Events in this range
- May 12, 2022Earnings: —; estimate -0.78; surprise —%
- Aug 11, 2022Earnings: —; estimate -0.92; surprise —%
- Nov 9, 2022Earnings: —; estimate -0.89; surprise —%
- Feb 28, 2023Earnings: —; estimate -0.91; surprise —%
- Apr 18, 2023Downgrade: Piper Sandler · Overweight → Neutral
- Apr 18, 2023Downgrade: RBC Capital · Outperform → Sector Perform
- Apr 18, 2023Downgrade: Credit Suisse · Outperform → Neutral
- Apr 18, 2023Downgrade: Wells Fargo · Overweight → Equal-Weight
- May 9, 2023Earnings: —; estimate -0.92; surprise —%
- May 10, 2023Downgrade: Jefferies · Buy → Hold
- May 10, 2023Rating: RBC Capital · — → Sector Perform
Signals (58)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | May 5, 2023 | 3 years ago |
| SMA: Bullish | Apr 17, 2023 | 3 years ago |
| RSI: Overbought | Apr 17, 2023 | 3 years ago |
| MACD: Buy Signal | Apr 6, 2023 | 3 years ago |
| SMA: Bearish | Mar 17, 2023 | 3 years ago |
| SMA: Bullish | Mar 16, 2023 | 3 years ago |
| SMA: Bearish | Mar 15, 2023 | 3 years ago |
| SMA: Bullish | Mar 13, 2023 | 3 years ago |
| SMA: Bearish | Mar 10, 2023 | 3 years ago |
| MACD: Sell Signal | Mar 9, 2023 | 3 years ago |
| MACD: Buy Signal | Mar 2, 2023 | 3 years ago |
| MACD: Sell Signal | Feb 23, 2023 | 3 years ago |
| MACD: Buy Signal | Feb 15, 2023 | 3 years ago |
| RSI: Overbought | Jan 11, 2023 | 3 years ago |
| MACD: Sell Signal | Dec 28, 2022 | 3 years ago |
| SMA: Bullish | Dec 7, 2022 | 3 years ago |
| SMA: Bullish | Dec 7, 2022 | 3 years ago |
| MACD: Buy Signal | Dec 7, 2022 | 3 years ago |
| RSI: Overbought | Dec 7, 2022 | 3 years ago |
| RSI: Oversold | Dec 5, 2022 | 3 years ago |
| SMA: Bearish | Dec 1, 2022 | 3 years ago |
| MACD: Sell Signal | Nov 4, 2022 | 3 years ago |
| SMA: Bearish | Oct 31, 2022 | 4 years ago |
| SMA: Bullish | Oct 27, 2022 | 4 years ago |
| MACD: Buy Signal | Oct 27, 2022 | 4 years ago |
| SMA: Bearish | Oct 11, 2022 | 4 years ago |
| MACD: Sell Signal | Oct 6, 2022 | 4 years ago |
| MACD: Buy Signal | Oct 3, 2022 | 4 years ago |
| MACD: Sell Signal | Sep 13, 2022 | 4 years ago |
| RSI: Overbought | Sep 7, 2022 | 4 years ago |
| MACD: Buy Signal | Sep 2, 2022 | 4 years ago |
| RSI: Overbought | Aug 31, 2022 | 4 years ago |
| MACD: Sell Signal | Aug 18, 2022 | 4 years ago |
| RSI: Overbought | Jul 25, 2022 | 4 years ago |
| SMA: Bullish | Jun 23, 2022 | 4 years ago |
| MACD: Buy Signal | Jun 21, 2022 | 4 years ago |
| MACD: Sell Signal | Jun 13, 2022 | 4 years ago |
| MACD: Buy Signal | Jun 3, 2022 | 4 years ago |
| MACD: Sell Signal | Jun 2, 2022 | 4 years ago |
| MACD: Buy Signal | May 13, 2022 | 4 years ago |
| MACD: Sell Signal | May 11, 2022 | 4 years ago |
| MACD: Buy Signal | May 3, 2022 | 4 years ago |
| RSI: Oversold | Apr 19, 2022 | 4 years ago |
| SMA: Bearish | Mar 24, 2022 | 4 years ago |
| MACD: Sell Signal | Mar 15, 2022 | 4 years ago |
| MACD: Buy Signal | Mar 9, 2022 | 4 years ago |
| RSI: Overbought | Mar 9, 2022 | 4 years ago |
| MACD: Sell Signal | Mar 4, 2022 | 4 years ago |
| RSI: Overbought | Feb 11, 2022 | 4 years ago |
| SMA: Bullish | Jan 28, 2022 | 4 years ago |
| MACD: Buy Signal | Jan 28, 2022 | 4 years ago |
| SMA: Bearish | Jan 27, 2022 | 4 years ago |
| SMA: Bullish | Jan 24, 2022 | 4 years ago |
| SMA: Bearish | Jan 21, 2022 | 4 years ago |
| SMA: Bullish | Jan 20, 2022 | 4 years ago |
| SMA: Bearish | Jan 19, 2022 | 4 years ago |
| SMA: Bullish | Jan 14, 2022 | 4 years ago |
| MACD: Sell Signal | Jan 10, 2022 | 4 years ago |
Key statistics
- Market cap
- 9.56B
- Enterprise value
- 8.87B
- Trailing P/E
- 0.00
- Forward P/E
- -44.33
- PEG ratio
- 0.00
- Price / sales
- 2392.62
- Price / book
- 13.67
- EPS (TTM)
- -3.54
- Beta
- -0.49
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 4.00M
- Revenue growth
- -71.80%
- Free cash flow
- -81.39M
- Total cash
- 713.67M
- Total debt
- 29.46M
- Return on equity
- -33.30%
- Shares outstanding
- 47.81M
- Short % of float
- 9.79%
- 50-day average
- 189.46
- 200-day average
- 112.93
Analyst view
Consensus: buy
Buy
Price target (mean) 190.00 -5.0% downside
Now 199.92
- Target (low)
- 160.00
- Target (mean)
- 190.00
- Target (high)
- 200.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 10, 2023
Expected Aug 10, 2023. Consensus EPS estimate -0.94.
Financials — quick view
RXDX Revenue — quarterly 1.10M
RXDX Net income — quarterly -40.88M
RXDX EPS — quarterly -0.86
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 10, 2023 | Jun 1, 2023 | -0.91 | — | — | — |
| May 9, 2023 | Mar 1, 2023 | -0.92 | — | — | — |
| Feb 28, 2023 | Dec 1, 2022 | -0.91 | — | — | — |
| Nov 9, 2022 | Sep 1, 2022 | -0.89 | — | — | — |
| Aug 11, 2022 | Jun 1, 2022 | -0.92 | — | — | — |
| May 12, 2022 | Mar 1, 2022 | -0.78 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 10, 2023 | RBC Capital | main | — | Sector Perform |
| May 10, 2023 | Jefferies | down | Buy | Hold |
| Apr 18, 2023 | Wells Fargo | down | Overweight | Equal-Weight |
| Apr 18, 2023 | Credit Suisse | down | Outperform | Neutral |
| Apr 18, 2023 | RBC Capital | down | Outperform | Sector Perform |
| Apr 18, 2023 | Piper Sandler | down | Overweight | Neutral |
About Prometheus Biosciences, Inc.
Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD, and inflammatory and fibrotic diseases. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH for PRA052; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. As of June 16, 2023, Prometheus Biosciences, Inc. operates as a subsidiary of Merck & Co., Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- prometheusbiosciences.com
News
- Merck beats on revenue boosted by Keytruda sales, but posts quarterly loss due to Prometheus deal
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RXDX, MDWT, RUTH
- PROMETHEUS BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prometheus Biosciences, Inc. - RXDX
- Prometheus Biosciences, Inc. (RXDX) is a Great Momentum Stock: Should You Buy?
- Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023
- Prometheus Biosciences, Inc. (RXDX) Reports Q1 Loss, Tops Revenue Estimates
- Here Are The Best-Performing Industry ETFs And Major Stock Contributors In April
- PROMETHEUS BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prometheus Biosciences, Inc. - RXDX
- Why Prometheus Biosciences Stock Is Skyrocketing This Week
- Why Merck Is Buying Prometheus Biosciences For About $10.8 Billion
Your note
Sign in to keep a note on RXDX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAMS HELEN C | Director | Stock Award(Grant) | May 18, 2023 | 2,674 |
| CEDARS SINAI INTELLECTUAL PROPERTY CO | Beneficial Owner of more than 10% of a Class of Security | Sale | Mar 7, 2023 | 0 |
| HASSAN FRED | Director | Stock Award(Grant) | May 18, 2023 | 2,123 |
| HENDRIX MARTIN | Director | Stock Award(Grant) | May 18, 2023 | 2,071 |
| LAUR JAMES | Director | Stock Award(Grant) | May 18, 2023 | 2,071 |
| MARSHALL KEITH W. | Chief Financial Officer | Conversion of Exercise of derivative security | Jun 1, 2023 | 87,973 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RTW Investments LP | 6.84% | 3,272,104 | 654.16M | Mar 30, 2023 |
| Blackrock Inc. | 5.86% | 2,799,818 | 559.74M | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 5.68% | 2,716,901 | 543.16M | Mar 30, 2023 |
| Boxer Capital, LLC | 3.97% | 1,897,500 | 379.35M | Mar 30, 2023 |
| 72 Investment Holdings, LLC | 3.87% | 1,848,024 | 369.46M | Mar 30, 2023 |
| Cormorant Asset Management, LP | 3.46% | 1,655,000 | 330.87M | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.23% | 1,060,681 | 212.05M | Dec 30, 2022 |
| Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund | 1.75% | 832,938 | 166.52M | Dec 30, 2022 |
| iShares Russell 2000 ETF | 1.61% | 765,275 | 152.99M | Feb 27, 2023 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 1.32% | 625,964 | 125.14M | Feb 27, 2023 |
| Vanguard Extended Market Index Fund | 0.98% | 465,623 | 93.09M | Dec 30, 2022 |
| Fidelity Select Portfolios - Biotechnology | 0.84% | 397,555 | 79.48M | Feb 27, 2023 |